journal article·2025-06Open access

Construction of a programmed activation nanosystem based on intracellular hypoxia in cisplatin-resistant tumor cells for reversing cisplatin resistance

Yurong Liu, Longqing Si, Yunheng Liu, Song Li, Xiaokang Zhang, Shaojing Jiang, Wenjing Liu, Xiaolin Li, Lianguo Zhang, Hongxia Zheng, Zhonghao Liu, Jinghui Hu, Jing Chen

Abstract

Cancer poses a significant threat to human life and health. Cancers treated with cisplatin invariably develop drug resistance. This challenge can be overcome by identifying and exploiting the vulnerabilities acquired by drug-resistant cancer cells, paving the way for finding effective novel treatment options for cisplatin-resistant cancers. Our previous study revealed that cisplatin resistance in cancer cells comes at the cost of increased intracellular hypoxia. In this study, we used 2-nitroimidazole modified hyaluronic acid (HA-NI) as the carrier. The cisplatin-resistant tumor cell specific intracellular hypoxia programmed activation nanomedicine (T/C@HN NPs) was constructed by the hypoxic toxic drug tirapazamine (TPZ) and encapsulating chlorin e6 (Ce6) into HA-NI using polymer assembly technology. The amphiphilic carrier could release free Ce6 molecules under the stimulation of intracellular hypoxic environment, and exhibit specific "activated state" photodynamic properties in cisplatin-resistant tumor cells. Upon irradiation, Ce6-mediated photodynamic therapy further intensifies hypoxia, amplifying its cytotoxicity. This project systematically evaluated the effects of T/C@HN NPs on the identification and recognition of cisplatin-resistant tumors using drug-resistant patient-derived xenograft (PDX) models. This study provides a promising avenue for the development of novel treatment of cisplatin-resistant tumors.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer, Hypoxia, and Metabolism · Photodynamic Therapy Research Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (58)

Show source-provided references
1. Platinum-based combination nanomedicines for cancer therapy10.1016/j.cbpa.2023.102290 ↗
2. H-dot mediated nanotherapeutics mitigate systemic toxicity of platinum-based anticancer drugs10.3390/ijms242015466 ↗
3. Platinum prodrug nanoparticles with COX-2 inhibition amplify pyroptosis for enhanced chemotherapy and immune activation of pancreatic cancer10.1002/adma.202310456 ↗
4. Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis10.1016/j.cmi.2023.08.029 ↗
5. Rewiring chaperone-mediated autophagy in cancer by a prion-like chemical inducer of proximity to counteract adaptive immune resistance10.1016/j.drup.2023.101037 ↗
6. Magnetic nanoparticles for ferroptosis cancer therapy with diagnostic imaging
7. Carvedilol for prevention of chemotherapy-related cardiotoxicity10.1016/j.jacc.2018.02.049 ↗
8. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery10.1097/SLA.0000000000005799 ↗
9. Exosomal circular RNAs: a chief culprit in cancer chemotherapy resistance10.1016/j.drup.2023.100937 ↗
10. Recent progress in nanomedicine for enhanced cancer chemotherapy10.7150/thno.57828 ↗
11. KYNU expression promotes cisplatin resistance in esophageal cancer10.7150/jca.93229 ↗
12. Optimal administration strategy in chemotherapy regimens using multi-drug cell-cycle specific tumor growth models
13. A multi-drug pharmacokinectic optimal control approach in cancer chemotherapy10.1007/s10957-022-02085-0 ↗
14. Reversing multi-drug resistance by polymeric metformin to enhance antitumor efficacy of chemotherapy10.1016/j.ijpharm.2022.121931 ↗
15. The resurgence of platinum-based cancer chemotherapy10.1038/nrc2167 ↗
16. Molecular mechanisms of cisplatin resistance10.1038/onc.2011.384 ↗
17. Nanoparticle-based drug delivery system: a patient-friendly chemotherapy for oncology10.1177/1559325820936161 ↗
18. Toxic epidermal necrolysis associated with chemoimmunotherapy for lymphoma: case report and literature review10.2217/imt-2021-0074 ↗
19. Nuclear-targeting lipid Pt IV prodrug amphiphile cooperates with siRNA for enhanced cancer immunochemotherapy by amplifying Pt-DNA adducts and reducing phosphatidylserine exposure10.1021/jacs.3c12706 ↗
20. Tumor acidic microenvironment-induced drug release of RGD peptide nanoparticles for cellular uptake and cancer therapy10.1016/j.colsurfb.2021.111673 ↗
21. Alliance with EPR effect: combined strategies to improve the EPR effect in the tumor microenvironment10.7150/thno.37198 ↗
22. Bioorthogonal guided activation of cGAS-STING by AIE photosensitizer nanoparticles for targeted tumor therapy and imaging10.1002/adma.202305668 ↗
23. A specific targeted enhanced nanotherapy strategy for inducing ferroptosis by regulating the iron pool levels in tumor cells10.1021/acsami.4c13534 ↗
24. Prodrug-based nano-delivery strategy to improve the antitumor ability of carboplatin in vivo and in vitro10.1080/10717544.2021.1938754 ↗
25. A NAG-guided nano-delivery system for redox- and pH-triggered intracellularly sequential drug release in cancer cells10.2147/IJN.S226249 ↗
26. Alteronol enhances the anti-tumor activity and reduces the toxicity of high-dose adriamycin in breast cancer10.3389/fphar.2019.00285 ↗
27. An acquired vulnerability of drug-resistant melanoma with therapeutic potential10.1016/j.cell.2018.04.012 ↗
28. Morusin, a novel inhibitor of ACLY, induces mitochondrial apoptosis in hepatocellular carcinoma cells through ROS-mediated mitophagy10.1016/j.biopha.2024.117510 ↗
29. A novel mechanism of 6-methoxydihydroavicine in suppressing ovarian carcinoma by disrupting mitochondrial homeostasis and triggering ROS/MAPK mediated apoptosis
30. Near-infrared-II light induced mild hyperthermia activate cisplatin-artemisinin nanoparticle for enhanced chemo/chemodynamic therapy and immunotherapy10.1002/smtd.202200379 ↗
31. Understanding the warburg effect: the metabolic requirements of cell proliferation10.1126/science.1160809 ↗
32. Cancer cell metabolism: warburg and beyond10.1016/j.cell.2008.08.021 ↗
33. Targeting cancer metabolism: a therapeutic window opens10.1038/nrd3504 ↗
34. SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism10.1158/1541-7786.MCR-07-2130 ↗
35. A natural compound-empowered podophyllotoxin prodrug nanoassembly magnifies efficacy-toxicity benefits in cancer chemotherapy
36. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism10.1016/j.canlet.2016.01.009 ↗
37. Self-enhanced targeted nanomedicines based on iron starvation acclimation for tumor-specific therapy10.1016/j.cej.2024.153371 ↗
38. Tumour hypoxia causes DNA hyper-methylation by reducing TET activity10.1038/nature19081 ↗
39. The anti-tumor efficacy of 20(S)-protopanaxadiol, an active metabolite of ginseng, according to fasting on hepatocellular carcinoma10.1016/j.jgr.2021.06.002 ↗
40. Breaking the intracellular redox balance with diselenium nanoparticles for maximizing chemotherapy efficacy on patient-derived xenograft models10.1021/acsnano.0c06190 ↗
41. Exploiting the acquired vulnerability of cisplatin-resistant tumors with a hypoxia-amplifying DNA repair-inhibiting (HYDRI) nanomedicine10.1126/sciadv.abc5267 ↗
42. Versatile nanomaterials that interfere with ferroptosis in the tumor microenvironment10.2147/IJN.S508767 ↗
43. A hypoxia-responsive albumin-based nanosystem for deep tumor penetration and excellent therapeutic efficacy10.1002/adma.201901513 ↗
44. MnOOH-catalyzed autoxidation of glutathione for reactive oxygen species production and nanocatalytic tumor innate immunotherapy10.1021/jacs.2c12942 ↗
45. Efficient piezocatalytic H2O2 production of atomic-level thickness Bi4Ti3O12 nanosheets with surface oxygen vacancy
46. Boosting ferroptosis via abplatin (iv) for treatment of platinum-resistant recurrent ovarian cancer10.1016/j.nantod.2022.101459 ↗
47. Modulating hypoxia via nanomaterials chemistry for efficient treatment of solid tumors10.1021/acs.accounts.8b00214 ↗
48. Magnesium silicide nanoparticles as a deoxygenation agent for cancer starvation therapy10.1038/nnano.2016.280 ↗
49. Openwork@Dendritic mesoporous silica nanoparticles for lactate depletion and tumor microenvironment regulation10.1002/anie.202001469 ↗
50. The effect of lengths of branched-chain fatty alcohols on the efficacy and safety of docetaxel-prodrug nanoassemblies10.1016/j.apsb.2023.09.017 ↗
51. Hypoxia-triggered tumor specific glutamine inhibition for reversing cisplatin resistance of chemotherapy10.1016/j.cej.2023.147692 ↗
52. Light-triggered retention and cascaded therapy of albumin-based theranostic nanomedicines to alleviate tumor adaptive treatment tolerance10.1002/adfm.201707291 ↗
53. Allyl-, butyl- and phenylethyl-isothiocyanate modulate Akt-mTOR and cyclin-CDK signaling in gemcitabine- and cisplatin-resistant bladder cancer cell lines10.3390/ijms231910996 ↗
54. Determination of the critical micelle concentration by absorbance and fluorescence techniques using fluorescein probe10.1016/j.cplett.2019.06.038 ↗
55. Determination of the critical premicelle concentration, first critical micelle concentration and second critical micelle concentration of surfactants by resonance Rayleigh scattering method without any probe10.1016/j.saa.2011.01.018 ↗
56. Metabolic pathway analysis using stable isotopes in patients with cancer10.1038/s41568-023-00632-z ↗
57. Moderate constraint facilitates association and force-dependent dissociation of HA-CD44 complex10.3390/ijms24032243 ↗
58. Overexpressed CD44 is associated with B-cell activation via the HA-CD44-AIM2 pathway in lupus B cells10.1016/j.clim.2023.109710 ↗